<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04503395</url>
  </required_header>
  <id_info>
    <org_study_id>FCRE-191125</org_study_id>
    <nct_id>NCT04503395</nct_id>
  </id_info>
  <brief_title>ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES</brief_title>
  <acronym>SOCRATES</acronym>
  <official_title>Physician Initiated Trial Investigating ESAR (EVAR Plus Heli-FX EndoAnchors) and FEVAR for the Treatment of Aortic Aneurysms With Short Infrarenal Aortic Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Giovanni Torsello</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FCRE (Foundation for Cardiovascular Research and Education)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized study is to compare the safety and performance of EndoVascular&#xD;
      Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using&#xD;
      customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda&#xD;
      Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness Endpoint - Technical Success</measure>
    <time_frame>through 12 months post-procedure</time_frame>
    <description>Composite of technical success at index procedure, and freedom from type IA or type III endoleak, freedom from aneurysm related mortality (ARM), and freedom from secondary reinterventions through 12 months post index procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Endpoint - Freedom from Major Adverse Events</measure>
    <time_frame>through 30 days post-procedure</time_frame>
    <description>Freedom from MAE through 30 days post index procedure. MAE defined as: All-Cause-Mortality, Bowel Ischemia, Myocardial Infraction, Procedural Blood Loss &gt; 1000cc, Access related complications, permanent paraplegia and paraparesis at 30 days, disabling stroke, respiratory failure, or renal complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total contrast volume (ml) at index procedure</measure>
    <time_frame>at index procedure</time_frame>
    <description>Total contrast volume (mL) at index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fluoroscopy time (minutes) at index procedure</measure>
    <time_frame>at index procedure</time_frame>
    <description>Total fluoroscopy time (minutes) at index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (minutes) of index procedure</measure>
    <time_frame>at index procedure</time_frame>
    <description>3. Duration (minutes) of index procedure (time between initial skin access to final closure of the last artery access site)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate penetration of endo anchors as accessed by the Core Lab</measure>
    <time_frame>at index procedure</time_frame>
    <description>Adequate penetration of endo anchors as accessed by the Core Lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>through 30 days post-procedure</time_frame>
    <description>7. Clinical success defined as technical success + freedom from intra-operative death and freedom from type IA/III endoleak in the first post-op image within 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral artery patency or occlusion at 1, 12, 24 and 36 months follow-up</measure>
    <time_frame>through 1,12,24 and 36-months post-op</time_frame>
    <description>Visceral artery patency or occlusion at 1, 12, 24 and 36 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from type Ia and III endoleaks at 1, 12, 24 and 36 months follow-up</measure>
    <time_frame>through 1,12,24 and 36-months post-op</time_frame>
    <description>Freedom from type Ia and III endoleaks at 1, 12, 24 and 36 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from aneurysm related secondary reinterventions at 1, 12, 24 and 36 months follow-up</measure>
    <time_frame>through 1,12,24 and 36-months post-op</time_frame>
    <description>Freedom from aneurysm related secondary reinterventions at 1, 12, 24 and 36 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from aneurysm related mortality at 1, 12, 24 and 36 months follow-up</measure>
    <time_frame>through 1,12,24 and 36-months post-op</time_frame>
    <description>Freedom from aneurysm related mortality at 1, 12, 24 and 36 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from stent graft migration (&gt;10mm change from 1-month follow-up imaging) at 12, 24 and 36 months follow-up</measure>
    <time_frame>through 12,24 and 36-months post-op</time_frame>
    <description>Freedom from stent graft migration (&gt;10mm change from 1-month follow-up imaging) at 12, 24 and 36 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sac dynamics (&gt;5mm change from 1-month follow-up imaging): increase, stable, decrease at 12, 24, and 36 months follow-up</measure>
    <time_frame>through 12,24 and 36-months post-op</time_frame>
    <description>Sac dynamics (&gt;5mm change from 1-month follow-up imaging): increase, stable, decrease at 12, 24, and 36 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from conversion to open repair at 1, 12, 24 and 36 months follow-up</measure>
    <time_frame>through 1,12,24 and 36-months post-op</time_frame>
    <description>Freedom from conversion to open repair at 1, 12, 24 and 36 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from AAA rupture at 1, 12, 24 and 36 months follow-up</measure>
    <time_frame>through 1,12,24 and 36-months post-op</time_frame>
    <description>Freedom from AAA rupture at 1, 12, 24 and 36 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall SCI rate, include transient events at 1 and 12 months follow-up</measure>
    <time_frame>through 1 and 12 months post-op</time_frame>
    <description>Overall SCI rate, include transient events at 1 and 12 months follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Aortic Aneurysm, Abdominal</condition>
  <arm_group>
    <arm_group_label>ESAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endovascular Aneurysm Repair + Heli-FX EndoAnchors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FEVAR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenestrated EndoVascular Aneurysm Repair</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ESAR treatment: Endograft + Heli-FX Endoanchor</intervention_name>
    <description>ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor</description>
    <arm_group_label>ESAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FEVAR treatment : Fenestrated endograft</intervention_name>
    <description>Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft</description>
    <arm_group_label>FEVAR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is &gt;18 years old&#xD;
&#xD;
          -  Subject is scheduled for primary treatment of the abdominal aortic aneurysm with a&#xD;
             non-aneurysmal infrarenal aortic sealing zone proximal to the aneurysm that is&#xD;
             sufficiently healthy for a proximal neck length that is at least 4mm and not more&#xD;
             than15 mm and has a circumferential minimum sealing zone length of 8 mm&#xD;
&#xD;
          -  Subject is not a candidate for safe and effective standard EVAR&#xD;
&#xD;
          -  Subject is able and willing to comply with the protocol and to adhere to the follow-up&#xD;
             requirements.&#xD;
&#xD;
          -  Subject has provided written informed consent&#xD;
&#xD;
          -  Subject is an eligible candidate according to the Endurant II/IIs + Heli-FX&#xD;
             EndoAnchor, Cook Zenith Fenestrated Graft, and Terumo Fenestrated Anaconda&#xD;
             Instructions For Use&#xD;
&#xD;
          -  Aortic neck diameter from 19 to 31mm&#xD;
&#xD;
          -  Iliac diameters with a range from 9 to 21mm&#xD;
&#xD;
          -  Infrarenal neck angulation ≤45°&#xD;
&#xD;
          -  Distal fixation length(s) of ≥30mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is participating in a concurrent study which may confound study results&#xD;
&#xD;
          -  Subject has a life expectancy &lt;2 year&#xD;
&#xD;
          -  Subject is female of childbearing potential in whom pregnancy cannot be excluded&#xD;
&#xD;
          -  Subject with eGFR &lt;30 mL/min/m2 (KDOQI classification - exclude class IV and above)&#xD;
             and or on dialysis&#xD;
&#xD;
          -  Subject with a MI or CVA within 3 months prior to index procedure&#xD;
&#xD;
          -  Subject with known Connective Tissue Disease&#xD;
&#xD;
          -  Subject has a known hypersensitivity or contraindication to anticoagulants,&#xD;
             antiplatelets, or contrast media, which is not amenable to post-treatment&#xD;
&#xD;
          -  Subject who has undergone prior endovascular or open surgical treatment for abdominal&#xD;
             aortic aneurysm&#xD;
&#xD;
          -  Subject requires emergent aneurysm treatment, for example, trauma or rupture&#xD;
&#xD;
          -  Subject has a known hypersensitivity or allergies to study device implant material&#xD;
&#xD;
          -  Subject has an aneurysm that is:&#xD;
&#xD;
               -  Suprarenal, pararenal, or thoracoabdominal&#xD;
&#xD;
               -  Mycotic&#xD;
&#xD;
               -  Inflammatory&#xD;
&#xD;
               -  Pseudoaneurysm&#xD;
&#xD;
          -  Subject is presenting with thrombus or calcification of the proximal aneurysm neck:&#xD;
             circumferential &gt;50%&#xD;
&#xD;
          -  Pre-op stenosis of the renal arteries &gt; 50%&#xD;
&#xD;
          -  Subject has active infection or history of COVID-19. History of COVID-19 is defined as&#xD;
             availability of positive COVID-19 test with sequelae or hospitalization for treatment&#xD;
             of COVID-19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Torsello, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>FCRE (Foundation for Cardiovascular Research and Education)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annelena Held-Wehmöller, PhD</last_name>
    <phone>+49 15785128140</phone>
    <email>info@fcre.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Ottakring, Institute for Vascular Surgery</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afshin Assadian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amrois Paré Hospital (APHP)</name>
      <address>
        <city>Boulogne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raphael Coscas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de lyon - Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Millon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrien Kaladji</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drosos Kotelis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dierk Scheinert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital LMU Munich</name>
      <address>
        <city>Munich</city>
        <zip>81337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nikolaos Tsilimparis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Franziskus-Hospital GmbH</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Bosiers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyriakos Oikonomou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VUMC Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kak Khee Yeung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Cuypers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrés Reyer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariano de Blas</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>FCRE (Foundation for Cardiovascular Research and Education)</investigator_affiliation>
    <investigator_full_name>Prof. Giovanni Torsello</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

